11/12
09:00 am
vinc
Vincerx Pharma Reports Third Quarter 2024 Financial Results
Medium
Report
Vincerx Pharma Reports Third Quarter 2024 Financial Results
10/8
11:48 am
vinc
Vincerx Pharma, Inc. (NASDAQ: VINC) had its price target lowered by analysts at Leerink Partners from $4.00 to $2.00. They now have an "outperform" rating on the stock.
High
Report
Vincerx Pharma, Inc. (NASDAQ: VINC) had its price target lowered by analysts at Leerink Partners from $4.00 to $2.00. They now have an "outperform" rating on the stock.
10/7
04:05 pm
vinc
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
High
Report
Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates